Clinical trials: Diffuse Large B Cell Lymphoma CD20 Positive, open to volunteers
CD20-positive Diffuse Large B-Cell Lymphoma
A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
This trial is a multicenter, open-label, single-arm, Phase II Study. Patients with CD20 positive recurrent or refractory diffuse large B-cell lymphoma and had failed ≥2 prior lines of standard treatment will be recruited.
- Trial name
- NCT06886139
- Testing
- TRS005
- Where
- China
- Volunteers
- 139 people
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
This trial is a multicenter, open-label, single-arm, dose-escalation and dose-expansion clinical trial. The dose was increased according to the "3 + 3" rule.
- Trial name
- NCT07035379
- Testing
- TRS005, Cyclophosphamide, Doxorubicin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.